Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: P072 Activity and clinical outcomes of New Agents (NAs) administered as third or fourth line after the failure of docetaxel (DOC) and another NA in metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. Final results of an Italian multicentr..., European Urology Supplements, November 2014, Elsevier,
DOI: 10.1016/s1569-9056(14)61295-1.
You can read the full text:

Read

Contributors

The following have contributed to this page